Back to Dashboard

D7401C00001

Lymphoma•NCT06549595•Last updated: 2/17/2026
Recruiting

Study Design

Study Drug

AZD0486

Mechanism of Action

CD19+CD3 bispecific Ab

Sponsor

Unknown

Design

III

Control Arm

AZD0486+Rituximab

Criteria

Inclusion Criteria

newly diagnosed + stage, III or IV disease, or stage II with bulky disease

Age: Phase: III

Exclusion Criteria

Enrollment

Progress1 / 10

Contact Information

Principal Investigator

Unknown

Study Nurse

吳宜真

Contact Tel

3974